Theravance, Inc.: Theravance Announces Positive Results of Clinical Program in Beyond Advair Collaboration
SOUTH SAN FRANCISCO, CA (MARKET WIRE) Theravance, Inc. (NASDAQ: THRX) today announced the results of two studies in an ongoing Phase 2b clinical program to assess the efficacy and safety of the investigational bronchodilators GSK642444 ('444) and GSK159797 ('797), the lead long-acting Beta2 agonist (LABA) compounds in the Beyond Advair collaboration with GlaxoSmithKline (GSK). In the studies, '444, a GSK-discovered compound, (Source: Market Wire - Pharmaceuticals and Biotech)
FDA Updates Safety Information for Long Acting Beta Agonists
Advair Diskus, Advair HFA, Brovana, Foradil, Serevent
Diskus, and Symbicort Information
(Long Acting Beta Agonists)
ROCKVILLE, Md., March 5, 2008-On November 18, 2005, FDA alerted
health care professionals and patients that several... (Source: Drugs.com - Pharma News)
